CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 480 enrolled
Drug / intervention
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg +2 moredrug
Likely dose
Desvenlafaxine Succinate Sustained-Release Formulation 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01056289
NCT01056289Phase 4Completed
CompareCT.gov

A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation

Pfizer·interventional·Posted Jan 26, 2010·Updated Feb 28, 2012

In Brief

A Phase 4 clinical trial evaluating Desvenlafaxine Succinate Sustained-Release Formulation 50 mg, Desvenlafaxine Succinate Sustained-Release Formulation 25 mg, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 480 participants.

Detailed Summary

Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 26, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.4 years ago

Interventions

Desvenlafaxine Succinate Sustained-Release Formulation 50 mgdrug

DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

Desvenlafaxine Succinate Sustained-Release Formulation 25 mgdrug

DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

Placebodrug

DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.